BRPI0519044B8 - anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso - Google Patents

anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso

Info

Publication number
BRPI0519044B8
BRPI0519044B8 BRPI0519044A BRPI0519044A BRPI0519044B8 BR PI0519044 B8 BRPI0519044 B8 BR PI0519044B8 BR PI0519044 A BRPI0519044 A BR PI0519044A BR PI0519044 A BRPI0519044 A BR PI0519044A BR PI0519044 B8 BRPI0519044 B8 BR PI0519044B8
Authority
BR
Brazil
Prior art keywords
directed against
antibody
antibody directed
antigen
monoclonal antibody
Prior art date
Application number
BRPI0519044A
Other languages
English (en)
Portuguese (pt)
Inventor
Gaucher Christine
De Romeuf Christophe
Prost Jean-François
Teillaud Jean-Luc
Original Assignee
Lab Francais Du Fractionnement
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Lfb Biotechnologies filed Critical Lab Francais Du Fractionnement
Publication of BRPI0519044A2 publication Critical patent/BRPI0519044A2/pt
Publication of BRPI0519044B1 publication Critical patent/BRPI0519044B1/pt
Publication of BRPI0519044B8 publication Critical patent/BRPI0519044B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0519044A 2004-12-15 2005-12-14 anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso BRPI0519044B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0413320 2004-12-15
FR0413320A FR2879204B1 (fr) 2004-12-15 2004-12-15 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
PCT/FR2005/003123 WO2006064121A2 (fr) 2004-12-15 2005-12-14 Anticorps cytotoxique dirige contre les proliferations hematopoïetiques lymphoïdes de type b

Publications (3)

Publication Number Publication Date
BRPI0519044A2 BRPI0519044A2 (pt) 2008-12-23
BRPI0519044B1 BRPI0519044B1 (pt) 2020-11-17
BRPI0519044B8 true BRPI0519044B8 (pt) 2021-05-25

Family

ID=34953790

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519044A BRPI0519044B8 (pt) 2004-12-15 2005-12-14 anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso

Country Status (16)

Country Link
US (2) US9234045B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1824887B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4999699B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR101340192B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101115772B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005315534B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2023C542I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0519044B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2590303C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1824887T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2588161T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2879204B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL183947A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL301242I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1824887T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006064121A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
CN101189003B (zh) 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
PL1912675T3 (pl) 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
FR2940616A1 (fr) * 2008-12-30 2010-07-02 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire.
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
FR2962908A1 (fr) * 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
FR2966043A1 (fr) * 2010-10-14 2012-04-20 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
MX382772B (es) * 2012-07-13 2025-03-11 Univ Pennsylvania Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
CN105073197B (zh) 2012-11-02 2019-06-28 Tg疗法有限公司 抗cd20抗体和pi3激酶选择性抑制剂的组合
BR112018073861A2 (pt) * 2016-05-20 2019-02-26 President And Fellows Of Harvard College métodos de terapia de genes para doenças e condições relacionadas com a idade
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
WO2018049263A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP4128227B2 (ja) * 1997-03-14 2008-07-30 バイオジェン・アイデック・インコーポレイテッド 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030003097A1 (en) * 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
ATE511654T1 (de) 2002-09-13 2011-06-15 Lfb Biotechnologies Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
CN1542132A (zh) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.

Also Published As

Publication number Publication date
BRPI0519044A2 (pt) 2008-12-23
CN101115772B (zh) 2012-10-17
IL183947A0 (en) 2007-10-31
EP2949674A1 (fr) 2015-12-02
US9873745B2 (en) 2018-01-23
AU2005315534B2 (en) 2011-11-10
FR23C1038I1 (fr) 2023-12-08
JP2012126724A (ja) 2012-07-05
CA2590303C (fr) 2015-05-26
WO2006064121A2 (fr) 2006-06-22
PL1824887T3 (pl) 2016-12-30
JP2008523793A (ja) 2008-07-10
AU2005315534A1 (en) 2006-06-22
US20090053233A1 (en) 2009-02-26
KR20140003660A (ko) 2014-01-09
KR20120023177A (ko) 2012-03-12
NL301242I2 (nl) 2023-11-01
JP4999699B2 (ja) 2012-08-15
CN101115772A (zh) 2008-01-30
BRPI0519044B1 (pt) 2020-11-17
JP5693440B2 (ja) 2015-04-01
EP1824887A2 (fr) 2007-08-29
WO2006064121A3 (fr) 2006-08-31
DK1824887T3 (en) 2016-09-05
US9234045B2 (en) 2016-01-12
NL301242I1 (nl) 2023-09-20
ES2588161T3 (es) 2016-10-31
CA2590303A1 (fr) 2006-06-22
KR101340192B1 (ko) 2013-12-12
FR2879204A1 (fr) 2006-06-16
KR20070102513A (ko) 2007-10-18
BE2023C542I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2025-02-07
FR23C1038I2 (fr) 2024-05-03
KR101418695B1 (ko) 2014-07-10
FR2879204B1 (fr) 2007-02-16
US20160060350A1 (en) 2016-03-03
EP1824887B1 (fr) 2016-05-25

Similar Documents

Publication Publication Date Title
BRPI0519044B8 (pt) anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
AR112564A2 (es) Anticuerpos humanizados contra el receptor del linfoma de burkitt (anti-cxcr5)
PH12015501763A1 (en) Humanized anti-factor d antibodies and uses thereof
CY1120018T1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
CY1116982T1 (el) Ανθρωποποιημενα αντισωματα αντι-παραγοντα d και χρησεις αυτων
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
MX2020001873A (es) Agentes de union.
HK1254861A1 (zh) 抗lag3抗體及其用途
EP4374922A3 (en) Anti-c5 antibodies and uses thereof
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
SA520420332B1 (ar) الأجسام المضادة لمكون مضاد للمتمم وطرق استخدامها
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
HN2004000356A (es) Anticuerpos dirigidos a m-csf
PE20200927A1 (es) Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
BR112022019060A2 (pt) Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
JOP20220117A1 (ar) مستقبلات المستضدات الخيمرية المضادة لـ cd79 وخلايا car التائية واستخداماتهما
BR112022015236A2 (pt) Composições de células t do receptor de antígeno quimérico direcionado a cd19 e métodos e usos das mesmas
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
AR065818A1 (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LFB BIOTECHNOLOGIES (FR)

Free format text: TRANSFERIDO DE: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR)